EZN-2208

DRUG5 trials

Sponsors

Enzon Pharmaceuticals, Inc., National Cancer Institute (NCI)

Conditions

Advanced Solid TumorsLymphomaMetastatic Breast CancerNeoplasmsSolid Tumors

Phase 1

A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)

CompletedNCT00520637

Enzon Pharmaceuticals, Inc.Advanced Solid Tumors, Lymphoma

Start: 2007-05-31Target: 34Updated: 2009-10-09

A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)

CompletedNCT00520390

Enzon Pharmaceuticals, Inc.Advanced Solid Tumors, Lymphoma

Start: 2007-05-31Target: 34Updated: 2010-04-02

EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors

CompletedNCT01251926

National Cancer Institute (NCI)Neoplasms

Start: 2010-11-15End: 2014-04-23Updated: 2019-11-15

Study of EZN-2208 Pediatric Patients With Solid Tumors

TerminatedNCT01295697

Enzon Pharmaceuticals, Inc.Solid Tumors

Start: 2010-02-28End: 2013-01-31Updated: 2022-02-14

Phase 2

A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer

TerminatedNCT01036113

Enzon Pharmaceuticals, Inc.Metastatic Breast Cancer

Start: 2009-11-30End: 2012-12-31Target: 160Updated: 2022-02-14